TGFB1 and neoplasm: NKG2D is an NK-cell activating receptor, but GBM exhibited decreased NKG2D-mediated tumor recognition and lysis due to TGF-β promoted down-regulation of NKG2D ligands on glioma cells [9] and NKG2D on NK and T cells [10].